Coherus BioSciences logo

Coherus BioSciences (CHRS) Q1 2026 Earnings

CHRS·Reported May 11, 2026·After market close

Coherus BioSciences reported Q1 2026 revenue of $12.3M (+62.0% YoY), missed analyst consensus of $14.2M by $1.9M. Diluted EPS came in at $-0.25 (+28.6% YoY), beat the $-0.26 consensus by $0.01.

Revenue
$12.3Mmissed by $1.9M
Consensus: $14.2M
Diluted EPS
$-0.25beat by $0.01
Consensus: $-0.26
SEC

SEC Filings

Earnings release8-K · 0001104659-26-058666
Quarterly report10-Q · 0001104659-26-058703

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Coherus BioSciences's Q1 2026 earnings report.

Coherus BioSciences (CHRS) reported Q1 2026 earnings on May 11, 2026 after market close.

Coherus BioSciences reported revenue of $12.3M and diluted EPS of $-0.25 for Q1 2026.

Revenue missed the consensus estimate of $14.2M by $1.9M. EPS beat the consensus estimate of $-0.26 by $0.01.

Compared to the same quarter a year prior, revenue grew 62.0% from $7.6M a year earlier and diluted EPS grew 28.6% from $-0.35.

You can read the 8-K earnings release (0001104659-26-058666) and the 10-Q periodic report (0001104659-26-058703) directly on SEC EDGAR. The filing index links above go to sec.gov.